St. Jude CEO: Medtronic's renal denervation miss doesn't dampen our spirits

January 13, 2014 by Arezu Sarvestani

St. Jude Medical president & CEO Dan Starks says that rival Medtronic's failed renal denervation study is no reason to stop pursuing the technology in treatment of hypertension.

St. Jude CEO: Medtronic's miss doesn't dampen our spirits

Get the complete picture with a MassDevice Plus membership. Registered users can login here.